IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
256 hedge funds and large institutions have $5.32B invested in IVERIC bio, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 106 funds opening new positions, 58 increasing their positions, 69 reducing their positions, and 73 closing their positions.
167% more funds holding in top 10
Funds holding in top 10: 15 → 40 (+25)
129% more call options, than puts
Call options by funds: $538M | Put options by funds: $234M
49% more capital invested
Capital invested by funds: $3.58B → $5.32B (+$1.74B)
45% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 73
15% more funds holding
Funds holding: 223 → 256 (+33)
16% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$206M |
| 2 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$188M |
| 3 |
Goldman Sachs
New York
|
+$114M |
| 4 |
TAL
TIG Advisors LLC
New York
|
+$103M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$100M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$238M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$160M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$158M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$126M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$102M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WTA
326
Washington Trust Advisors
Wellesley,
Massachusetts
| – | -$1.44K | -59 | Closed |
|
327
Parallax Volatility Advisers
San Francisco,
California
| – | -$1.69K | -48 | Closed |
|
|
BAM
328
Belpointe Asset Management
Reno,
Nevada
| – | -$243 | -10 | Closed |
|
|
AAS
329
Ameritas Advisory Services
Lincoln,
Nebraska
| – | -$253 | -8 | Closed |
|
ISEE Hedge Fund Activity: Q2 2023 in Review
256 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q2 2023, worth a combined $5.32B — up 49% from $3.58B a quarter earlier.
Buyers outnumbered sellers: 106 funds opened new ISEE positions and 73 closed out — a net gain of 33 holders — while 58 added to existing stakes and 69 trimmed.
The largest buyer was UBS O'Connor, opening a new position worth an estimated $206M. The largest seller was T. Rowe Price Associates, cutting an estimated $238M.
- 256 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q2 2023, up from 223 in Q1 2023.
- Funds reported $5.32B of IVERIC bio, Inc. Common Stock stock for Q2 2023, up 49% quarter-over-quarter.
- 106 funds opened new IVERIC bio, Inc. Common Stock positions in Q2 2023 and 73 closed out, a net change of +33 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q2 2023 was UBS O'Connor, an estimated $206M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q2 2023 was T. Rowe Price Associates, an estimated $238M sold.
Based on aggregated 13F filings for Q2 2023.